PHA
-
DATABASE (66)
-
ARTICLES (2)
Business Developer and Founder of The Beemine Lab
Telmo Güell is a young entrepreneur responsible for the business development of The Beemine Lab, the first biotechnology company in Spain to produce cannabidiol-based cosmetics. He founded the company in 2018. Güell started his studies in Philosophy but he soon realized he was more fascinated by design and computer programming and so chose to specialize in JavaScript Fullstack and UX. Passionate about bees, he decided to start a project that would support beekeeping and address the risk of bee extinction. By combining bees with the cannabis plant, he founded The Beemine Lab, using bees to pollinate cannabis plants and cannabis pollen to sustain populated beehives.The Beemine Lab products are today sold in pharmacies, para-pharmacies and via Amazon Spain, as well as on the company’s e-commerce page.
Telmo Güell is a young entrepreneur responsible for the business development of The Beemine Lab, the first biotechnology company in Spain to produce cannabidiol-based cosmetics. He founded the company in 2018. Güell started his studies in Philosophy but he soon realized he was more fascinated by design and computer programming and so chose to specialize in JavaScript Fullstack and UX. Passionate about bees, he decided to start a project that would support beekeeping and address the risk of bee extinction. By combining bees with the cannabis plant, he founded The Beemine Lab, using bees to pollinate cannabis plants and cannabis pollen to sustain populated beehives.The Beemine Lab products are today sold in pharmacies, para-pharmacies and via Amazon Spain, as well as on the company’s e-commerce page.
CEO and co-founder of String Bio
Ezhil Subbian studied industrial biotechnology at Anna University in India. She then went to the US to complete two PhDs in biochemistry, biophysics and molecular biology at the Oregon Health & Science University and from Rutgers, the State University of New Jersey-New Brunswick. She was a research assistant at both universities.While in the US, she was also a research scientist at Gevo Inc and at Vollum Institute. In 2008, she became a scientist and technical lead at pharma Codexis in California. In 2011, she worked at San Francisco-based Kumar Investments as an entrepreneur and biotech consultant.In 2012, she founded biotech startup String Inc while on a nine-month Startup Leadership Program in Silicon Valley. In June 2013, she and husband returned to India and formed a new company String Bio to continue working on the alternative protein powder project for animal feed production.
Ezhil Subbian studied industrial biotechnology at Anna University in India. She then went to the US to complete two PhDs in biochemistry, biophysics and molecular biology at the Oregon Health & Science University and from Rutgers, the State University of New Jersey-New Brunswick. She was a research assistant at both universities.While in the US, she was also a research scientist at Gevo Inc and at Vollum Institute. In 2008, she became a scientist and technical lead at pharma Codexis in California. In 2011, she worked at San Francisco-based Kumar Investments as an entrepreneur and biotech consultant.In 2012, she founded biotech startup String Inc while on a nine-month Startup Leadership Program in Silicon Valley. In June 2013, she and husband returned to India and formed a new company String Bio to continue working on the alternative protein powder project for animal feed production.
Chief Growth Officer and co-founder of Kobo360
After graduating in business administration at the University of Michigan-Dearborn in 2013, Ife Oyedele II stayed on at the university to obtain a master’s in information technology in 2016.While studying in Michigan, Oyedele met up with Obi Ozor and the two friends started an e-commerce venture to sell diapers and baby soap from the US to customers in Nigeria. Ozor later moved to Philadelphia to continue his studies at Wharton School.Still at university, he gained work experience in business intelligence at Michigan consultancy firm CFI Group for about three years. He has also conducted some research for pharma group iLabs and completed stints in business analysis and quality assurance at various companies. In May 2014, he joined General Fuels company in Detroit and worked as a business manager for almost two years.In 2016, Ozor and Oyedele co-founded Uber-style logistics platform Kobo360 in Nigeria. Oyedele was CTO at Kobo360 until 2020 when he became the company’s Chief Growth Officer.
After graduating in business administration at the University of Michigan-Dearborn in 2013, Ife Oyedele II stayed on at the university to obtain a master’s in information technology in 2016.While studying in Michigan, Oyedele met up with Obi Ozor and the two friends started an e-commerce venture to sell diapers and baby soap from the US to customers in Nigeria. Ozor later moved to Philadelphia to continue his studies at Wharton School.Still at university, he gained work experience in business intelligence at Michigan consultancy firm CFI Group for about three years. He has also conducted some research for pharma group iLabs and completed stints in business analysis and quality assurance at various companies. In May 2014, he joined General Fuels company in Detroit and worked as a business manager for almost two years.In 2016, Ozor and Oyedele co-founded Uber-style logistics platform Kobo360 in Nigeria. Oyedele was CTO at Kobo360 until 2020 when he became the company’s Chief Growth Officer.
Founder and CEO of Yidianling
Xu Yingqi has over a decade of work experience in the gaming, pharmaceutical and finance sectors. He joined an online gaming company named 5173 in 2003 and expanded the team from 20 to 3,000 employees, increasing the yearly GMV from US$3m to more than US$1.5bn. Xu then joined a pharmaceutical company named 818 in 2009, helping over 300 pharmacies go online. The company's business grew 248% annually under his leadership. In 2003, Xu started financial services platform 658 that generated RMB1.3bn worth of transactions. In 2015, he went on to establish Yidianling, an online mental health consultancy.
Xu Yingqi has over a decade of work experience in the gaming, pharmaceutical and finance sectors. He joined an online gaming company named 5173 in 2003 and expanded the team from 20 to 3,000 employees, increasing the yearly GMV from US$3m to more than US$1.5bn. Xu then joined a pharmaceutical company named 818 in 2009, helping over 300 pharmacies go online. The company's business grew 248% annually under his leadership. In 2003, Xu started financial services platform 658 that generated RMB1.3bn worth of transactions. In 2015, he went on to establish Yidianling, an online mental health consultancy.
Co-founder, CTO of SwissDeCode
Gianpaolo Rando is CTO and co-founder at Swiss biotech SwissDeCode, which applies DNA testing to food traceability. He has worked there full-time since April 2016. Prior to this, Rando gained significant experience working in the field of genomics. He spent three years prior to SwissDeCode’s foundation trialing his DNA food testing technology in his startup BeerDeCoded and assisted in the launch of a compact DNA laboratory at Bento Bio in London. He previously spent almost three years at the University of Geneva in research, co-inventing a technology for ink to change color in response to a specific DNA sequence. His earlier position at the University of Lausanne as a post-doctoral fellow in genomics saw him lead a nine-man team for three and a half years, discovering the hormone that prepares newborns to lactate. Rando’s first post was at Trangenic Operative Products, leading animal research there. Italian-born Rando holds a PhD in biotechnology and pharmacology from the University of Milan as well as a qualification in data science.
Gianpaolo Rando is CTO and co-founder at Swiss biotech SwissDeCode, which applies DNA testing to food traceability. He has worked there full-time since April 2016. Prior to this, Rando gained significant experience working in the field of genomics. He spent three years prior to SwissDeCode’s foundation trialing his DNA food testing technology in his startup BeerDeCoded and assisted in the launch of a compact DNA laboratory at Bento Bio in London. He previously spent almost three years at the University of Geneva in research, co-inventing a technology for ink to change color in response to a specific DNA sequence. His earlier position at the University of Lausanne as a post-doctoral fellow in genomics saw him lead a nine-man team for three and a half years, discovering the hormone that prepares newborns to lactate. Rando’s first post was at Trangenic Operative Products, leading animal research there. Italian-born Rando holds a PhD in biotechnology and pharmacology from the University of Milan as well as a qualification in data science.
Founder and CEO of Alodokter
A graduate with a master’s in Management and Business Strategy from the ESSEC Business School Paris, Nathanael Faibis had worked for two years as a project manager in France, Kenya and Morocco for a pharmaceutical market research company Sanisphere. In 2012, he worked for Lazada in Vietnam and Indonesia before becoming the head of production and user experience of Lazada Southeast Asia. However, he left Lazada in March 2013 to rejoin Sanisphere in Jakarta as the country head and global head of data management. Finally in April 2014, he decided to set up an Indonesian health portal Alodokter.
A graduate with a master’s in Management and Business Strategy from the ESSEC Business School Paris, Nathanael Faibis had worked for two years as a project manager in France, Kenya and Morocco for a pharmaceutical market research company Sanisphere. In 2012, he worked for Lazada in Vietnam and Indonesia before becoming the head of production and user experience of Lazada Southeast Asia. However, he left Lazada in March 2013 to rejoin Sanisphere in Jakarta as the country head and global head of data management. Finally in April 2014, he decided to set up an Indonesian health portal Alodokter.
Chairman and Founder of Dingdang Medicine Express
Born in Jiangxi Province in 1962, Yang Wenlong is a traditional Chinese pharmacist and senior economist. The MBA graduate from Cheung Kong Graduate School of Business ran a traditional Chinese medicine business from 1982 to 1987 in Zhangshu. He also founded the Jiangxi Kangmei Medical & Healthcare Co Ltd in 1998 and the Renhe Group in 2001.He is the chairman of Renhe Group and Dingdang Medicine Express. He is a member of the national committee of the Chinese People's Political Consultative Conference (CPPCC) and a member of the central committee of the China National Democratic Construction Association.
Born in Jiangxi Province in 1962, Yang Wenlong is a traditional Chinese pharmacist and senior economist. The MBA graduate from Cheung Kong Graduate School of Business ran a traditional Chinese medicine business from 1982 to 1987 in Zhangshu. He also founded the Jiangxi Kangmei Medical & Healthcare Co Ltd in 1998 and the Renhe Group in 2001.He is the chairman of Renhe Group and Dingdang Medicine Express. He is a member of the national committee of the Chinese People's Political Consultative Conference (CPPCC) and a member of the central committee of the China National Democratic Construction Association.
Advisor, board member, co-founder of NovoNutrients
Brian Sefton has been co-founder, a board member and a part-time advisor at NovoNutrients, a San Francisco-based biotech manufacturer of alt-protein produced from fermentation and CO2 since it was founded in 2017. In 2009, he co-founded research entity Oakbio, from which NovoNutrients evolved, and was its President and CTO. Sefton was CTO and President at NovoNutrients and also co-CEO and Chief Scientist at Oakbio until 2021 when he became the CEO at San Francisco-based fermentation commercialization startup Sincarne. Between 2005 and 2011, Sefton was also CEO at pharma research company Pharmadyn, working on drugs development for Alzheimer's Disease, and, for three of those years, was also Managing Partner of Stratsyn, a consultancy specializing in creation, development, management and fund raising for not-for-profit organizations. Sefton’s earlier posts include: directing nanotechnology commercialization and investment company Nanosig for three years, CEO of Silicon Valley’s Fastlane, a high-profile pioneer in real-time network traffic and security analysis for six years; and, simultaneously, being CEO at Bluebox Communications, developing high-end network security applications and appliances for Fortune 500 companies and the US government.Sefton holds an MBA from Santa Clara University in California and a bachelor’s degree in biochemistry from the University of California, Berkeley
Brian Sefton has been co-founder, a board member and a part-time advisor at NovoNutrients, a San Francisco-based biotech manufacturer of alt-protein produced from fermentation and CO2 since it was founded in 2017. In 2009, he co-founded research entity Oakbio, from which NovoNutrients evolved, and was its President and CTO. Sefton was CTO and President at NovoNutrients and also co-CEO and Chief Scientist at Oakbio until 2021 when he became the CEO at San Francisco-based fermentation commercialization startup Sincarne. Between 2005 and 2011, Sefton was also CEO at pharma research company Pharmadyn, working on drugs development for Alzheimer's Disease, and, for three of those years, was also Managing Partner of Stratsyn, a consultancy specializing in creation, development, management and fund raising for not-for-profit organizations. Sefton’s earlier posts include: directing nanotechnology commercialization and investment company Nanosig for three years, CEO of Silicon Valley’s Fastlane, a high-profile pioneer in real-time network traffic and security analysis for six years; and, simultaneously, being CEO at Bluebox Communications, developing high-end network security applications and appliances for Fortune 500 companies and the US government.Sefton holds an MBA from Santa Clara University in California and a bachelor’s degree in biochemistry from the University of California, Berkeley
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Formerly Fidelity Growth Partners, the renamed Eight Roads Ventures is the investment arm of Fidelity International Limited. In China for over 20 years, it counts among its successful investments/exits Alibaba, WuXi PharmaTech, AsiaInfo and iSoftStone. It focuses on early- and growth-stage companies across eight broad sectors.
Formerly Fidelity Growth Partners, the renamed Eight Roads Ventures is the investment arm of Fidelity International Limited. In China for over 20 years, it counts among its successful investments/exits Alibaba, WuXi PharmaTech, AsiaInfo and iSoftStone. It focuses on early- and growth-stage companies across eight broad sectors.
A spinoff from Chinese investment bank China International Capital Corp, CDH has its roots in private equity. It started in 2002, raising its first fund of US$102 million. As of end-2015, it had over US$15 billion in assets under management, spanning private equity, public equities, real estate and more. It has invested in more than 150 companies, including WH Group, Belle International, Mengniu Dairy, Qihoo 360 and Luye Pharma; and has offices in Beijing, Hong Kong, Shanghai, Shenzhen, Singapore and Jakarta.
A spinoff from Chinese investment bank China International Capital Corp, CDH has its roots in private equity. It started in 2002, raising its first fund of US$102 million. As of end-2015, it had over US$15 billion in assets under management, spanning private equity, public equities, real estate and more. It has invested in more than 150 companies, including WH Group, Belle International, Mengniu Dairy, Qihoo 360 and Luye Pharma; and has offices in Beijing, Hong Kong, Shanghai, Shenzhen, Singapore and Jakarta.
Portuguese state investment company PME Investimentos is the country's most prolific tech investor. Founded in 1989 as a joint stock company, SULPEDIP was under the supervision of the Bank of Portugal and changed its name to PME in 1998. The main aim is to help local SMEs to access funding and financial management services to develop and expand internationally. PME has invested in hundreds of startups, both tech and non-tech focused, across market verticals. It also manages several funds, including 200M that was launched in 2016 to focus on investments in Portugal-based startups. The co-investment fund of €200m prioritizes startups based in the Northern, Central, Alentejo, Lisbon and Algarve regions. The fund matches up to 100% of the private investors’ commitment, subject to a minimum investment of €500,000 and a maximum of €5m. Recent investments include petfood e-commerce Barkyn's €1.1m seed round, €4.2m Series A of made-to-order designer Platforme and a €650,000 contribution in the second phase of healthy food service EatTasty's €1.75m seed round.
Portuguese state investment company PME Investimentos is the country's most prolific tech investor. Founded in 1989 as a joint stock company, SULPEDIP was under the supervision of the Bank of Portugal and changed its name to PME in 1998. The main aim is to help local SMEs to access funding and financial management services to develop and expand internationally. PME has invested in hundreds of startups, both tech and non-tech focused, across market verticals. It also manages several funds, including 200M that was launched in 2016 to focus on investments in Portugal-based startups. The co-investment fund of €200m prioritizes startups based in the Northern, Central, Alentejo, Lisbon and Algarve regions. The fund matches up to 100% of the private investors’ commitment, subject to a minimum investment of €500,000 and a maximum of €5m. Recent investments include petfood e-commerce Barkyn's €1.1m seed round, €4.2m Series A of made-to-order designer Platforme and a €650,000 contribution in the second phase of healthy food service EatTasty's €1.75m seed round.
Established in 1863, Bayer is a global chemical and pharmaceutical company with its head office in Leverkusen, Germany. In 2015, the company launched its digital healthcare accelerator program Grants4Apps in Berlin. Bayer has worldwide operations in cities like San Francisco, Tokyo, Shanghai, Singapore and Moscow.
Established in 1863, Bayer is a global chemical and pharmaceutical company with its head office in Leverkusen, Germany. In 2015, the company launched its digital healthcare accelerator program Grants4Apps in Berlin. Bayer has worldwide operations in cities like San Francisco, Tokyo, Shanghai, Singapore and Moscow.
Established in January 2015, Riverhead Capital Investment Management Co., Ltd. is among the first batch of insurance private equity fund pilot units approved by the China Insurance Regulatory Commission. With assets under management of RMB 17 billion, it mainly invests in medical, pharmaceutical, Internet, innovative financial services and other fields.
Established in January 2015, Riverhead Capital Investment Management Co., Ltd. is among the first batch of insurance private equity fund pilot units approved by the China Insurance Regulatory Commission. With assets under management of RMB 17 billion, it mainly invests in medical, pharmaceutical, Internet, innovative financial services and other fields.
Capitana Venture Partners is a venture fund headquartered in Madrid with a presence across Spain, Germany, Italy and UK. The firm backs technology startups at their seed and early stage phase, investing between €200,000 and €500,000. Capitana's team comprises eight business angels and advisors with experience in corporate finance, investment banking and capital market financing.
Capitana Venture Partners is a venture fund headquartered in Madrid with a presence across Spain, Germany, Italy and UK. The firm backs technology startups at their seed and early stage phase, investing between €200,000 and €500,000. Capitana's team comprises eight business angels and advisors with experience in corporate finance, investment banking and capital market financing.
Bluepha to boost PHA bioplastics production with $30m fresh funding
The Beijing-based startup aims to produce 10,000 tons of PHA bioplastic a year and build a SynBio community through its STEM education spinoff, Bluepha Lab
VEnvirotech: Organic waste converted at source into biodegradable raw bioplastic
The Spanish startup presents an innovative circular business model to stand out in the ever-growing bioplastics sector with its on-site smart-waste container and garbage-consuming bacteria
Sorry, we couldn’t find any matches for “PHA”.
1
POPULAR DATABASE
